(EMAILWIRE.COM, November 09, 2020 ) The Cell Surface Markers Market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, growing at a CAGR of 8.1% during the forecast period.

The growth of this market is driven by factors such as the high global prevalence of cancer, growth in stem cell and neurobiology research, and the increasing funding for life sciences research.

Clinical Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period

Based on application, the cell surface markers market is segmented into research applications and clinical applications. The clinical applications segment is expected to witness higher growth during the forecast period primarily due to the rising prevalence of cancer and the increasing adoption of cell surface markers in cancer treatment.

Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216278622

Hospitals & Clinical Testing Laboratories use Cell Surface Markers for the Diagnosis of Various Diseases

On the basis of end user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. The hospitals & clinical testing laboratories segment is expected to register the highest CAGR during the forecast period.

North America is expected to be the largest regional market for cell surface markers in 2018

The global cell surface markers market is segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World. In 2018, North America is expected to account for the largest share of the market. The large share of the North American market is attributed to factors such as the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development.

Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=216278622

Leading Players

Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US)